Physician profile

Paul E Fracasso

Family Medicine · Rittman, OH

NPI 1891786232

$901.16

in general payments reported to CMS, 2019-2025

18 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $284.93 2019-2020
Novartis Pharmaceuticals Corporation $99.67 2019-2020
Glaxosmithkline, LLC. $93.45 2019-2020
Astrazeneca Pharmaceuticals LP $81.83 2019-2020
Janssen Pharmaceuticals, INC $77.87 2019-2020
Sanofi-Aventis U.S. LLC $57.35 2019-2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $34.48 2019
Amarin Pharma, INC. $25.43 2019-2020
Abbott Laboratories $22.19 2022
Pfizer INC. $19.82 2019
Lilly USA, LLC $14.95 2020
Avanir Pharmaceuticals, INC. $14.85 2019
Mannkind Corporation $14.76 2019
Ironwood Pharmaceuticals, INC $13.54 2019
Allergan, INC. $12.42 2019
Show all 18 companies
CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $11.75 2019
Merck Sharp & Dohme LLC $10.95 2019
Novo Nordisk INC $10.92 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Paul E Fracasso

$901.16

in general payments reported 2019-2025

Years
2019-2022
Top company
Amgen INC.

https://glasscript.com/doctor/267453/paul-e-fracasso

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.